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ABSTRACT
INTRODUCTION: Despite available evidence for a link between bone health and arterial hypertension 
(AH), the results of clinical trials remain conflicting. Thus, we conducted a cross-sectional study to analyze 
a possible association between blood pressure (BP), antihypertensive therapy and deteriorating bone health 
in postmenopausal women.
MATERIALS AND METHODS: The study included 84 women from Northeastern Bulgaria. Their mean 
age was 60.54±7.07 years, and their mean duration of menopause was 11.45±6.62 years. Bone health was as-
sessed by dual-energy X-ray absorptiometry (DEXA) and by analysis of bone metabolic markers.
RESULTS: A significant negative correlation was established between bone mineral density (BMD) and di-
astolic BP. On the other hand, AH predominated in the studied population. However, among the subjects di-
agnosed with osteopenia and osteoporosis, a significantly higher proportion of AH was observed. In addi-
tion, differences were found according to the stage of AH and according to the intake of antihypertensive 
therapy, when assessing BMD and fracture risk. In subjects with newly diagnosed and respectively untreat-
ed AH as well as in the group of stage III AH, the lowest BMD and the highest fracture risk were found. Al-
though we reported a significant difference in the mean age of women according to the presence of AH and 
its stages, after further analysis it was found that the presence of AH is an independent risk factor for bone 
health in postmenopausal women (OR=2.14 (0.686–6.703); p=0.015).
CONCLUSION: According to the obtained results, we assumed that AH was risk factor for bone health 
in postmenopausal women, as it was associated with lower BMD and higher fracture risk. In addition, we 
found differences according to the stage of AH and antihypertensive therapy, which might be considered in 
the prevention, prophylaxis and treatment of osteoporosis.
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It is known that the incidence of both arterial 
hypertension (AH) and osteoporosis increases with 
age. A number of researchers have suggested that the 
two diseases share certain similarities in etiology and 
pathogenesis, but the results of clinical observations 
on the relationship between bone health and blood 
pressure (BP) remain conflicting. Some studies have Received: October 7, 2021
Accepted: October 19, 2021
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MATERIALS AND METHODS
The study analyzed 84 women from North-
eastern Bulgaria. Inclusion criteria: рostmenopausal 
women with a missing menstrual cycle of ≥1 year. 
Exclusion criteria: 1. iatrogenic and premature meno-
pause (<40 years); 2. current or past use of drugs that 
affect bone metabolism (hormone therapy, cortico-
steroids, anticonvulsants, drugs for the treatment of 
osteoporosis); 3. malignancy; 4. acute and chronic in-
flammation; 5. thyroid and parathyroid dysfunction; 
6. limited physical activity (immobilization, paraly-
sis) 7. liver and/or kidney disease; 8. known diabe-
tes mellitus.
After signing an informed consent, the partici-
pants underwent a structured medical interview and 
thorough medical examination. Systolic and diastol-
ic BP measurements were taken with a calibrated 
sphygmomanometer on the dominant arm when the 
patients were in sitting position, 10 minutes after rest. 
The mean values of three measurements performed 
at an interval of 5 minutes were used for analysis.
Arterial hypertension was defined as systolic 
BP ≥130 mmHg and/or diastolic BP ≥ 85 mmHg or 
a history of antihypertensive therapy. In the present 
study, these values  are accepted in view of the cat-
egories of BP according to the 2017 ACC/ANA rec-
ommendations, where values  of systolic BP 130–139 
mmHg or diastolic BP 80–89 mmHg are classified as 
stage I AH (9). On the other hand, according to the 
2018 ESC/ESH recommendations, BP values of sys-
tolic BP 130–139 mmHg and/or diastolic BP 85–89 
mmHg are defined as high normal BP, but in some 
of the cases antihypertensive therapy may be con-
sidered (10). However, we took into account that BP 
has not been monitored to confirm AH in individ-
uals with newly diagnosed AH. On the other hand, 
some of the subjects with newly diagnosed AH fell 
into the category of high normal BP according to the 
recommendations of 2018 ESC/ESH. In this regard, 
in subsequent analyses, we performed additional cal-
culations after separating the group with newly di-
agnosed AH from patients with known AH. De-
pending on the presence and the degree of damage 
to the target organs, according to the WHO classifi-
cation, the participants with AH were divided into 3 
groups: Stage I AH—without organ damage; Stage II 
found a negative correlation between AH and bone 
health (1,2,3,4). Much of the collected data suggest 
that AH could be a factor leading to a decrease in 
bone density and an increase in fracture risk (1,3). 
On the other hand, a study from Canada, conducted 
among a large group of men and women, found that 
AH was associated with an increase in bone mass 
and a decrease in the number of vertebral deformi-
ties. The effect is maintained after adjustment for 
age, weight, use of estrogens and thiazides (5). How-
ever, the results of other studies suggest that there is 
no correlation between AH and bone density (6,7). 
Javed et al., for example, in their retrospective study 
found that in patients with and without AH, the pro-
portion of subjects with both osteopenia and osteo-
porosis was similar (6). Hijazi et al. also did not es-
tablish a link between osteoporosis and AH in post-
menopausal women (7).
The presence conflicting data in the literature 
on the relationship between bone health and AH 
may be related to differences in the degree and stage 
of AH among the studied populations, as well as to 
the control of BP. It should be noted that not all stud-
ies clearly report whether subjects were receiving an-
tihypertensive therapy. However, antihypertensive 
drugs, which have specific effects on various target 
organs, could also affect bone health. For example, 
thiazide diuretics, beta blockers (BBs), nitrates, and 
spironolactone are considered to have beneficial ef-
fects on bone (7,8). It has been suggested also that an-
giotensin-converting enzyme inhibitors (ACEi) and 
angiotensin-receptor blockers (ARBs) might be use-
ful in patients with AH and impaired bone health, 
although there is different data on their effects on 
calcium-phosphorus metabolism and bone mass (8). 
Data on Ca-antagonists and bone health are limited 
and inconclusive, but it appears unlikely that these 
drugs have any clinically significant effect on bone 
(8). On the other hand, it is accepted that loop diuret-
ics have a negative effect on bone integrity and are as-
sociated with an increased risk of fractures (8).
AIM
The aim of the study was to establish a possi-
ble association between BP, antihypertensive therapy 
and bone health in postmenopausal women.
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AH—mild organ damage; Stage III AH—severe or-
gan damage.
The measurement of BMD and T score at the 
level of lumbar spine and proximal femur by du-
al-energy X-ray absorptiometry (DEXA) was per-
formed with a LUNAR PRODIGY BX-1L (GE MED-
ICAL, MEDISON, WI, USA). Blood samples for 
analysis of bone metabolic markers were taken in the 
morning in fasting state. The bone formation mark-
er osteocalcin was determined by chemiluminescent 
immunoassay (Immulite 2000). The bone resorption 
marker Beta-crossLaps was determined by electro-
chemiluminescent immunoassay (Cabas 6000). The 
bone resorption marker Pyrilinks-D was determined 
by enzymatic chemiluminescent immunoassay (Im-
mulite 2000). The method determines the amount of 
deoxypyridinoline in the urine. The results are pre-
sented as the ratio of Pyrilinks-D and creatinine in 
the first portion of morning urine. The 10-year prob-
ability of hip fractures (HF) and the 10-year prob-
ability of major osteoporotic fractures (MOF) were 
determined using the Fracture Risk Assessment Tool 
(FRAX). The fracture risk calculation was performed 
according to a formula for the Caucasian race using 
a femoral neck BMD (g/cm2) (www.sheffield.ac.uk/
FRAX/tool.aspx?country=9).
Statistical analysis
Data were processed with SPSS v.20.0 for Win-
dows by performing dispersion analysis (ANOVA); 
variation analysis; correlation analysis (Pearson’s R; 
Spearman correlation); risk assessment (OR) analy-
sis; comparative analysis (hypothesis evaluation)—
χ2, t-test. For all performed analyses, the statistical 
significance was set as p<0.05 with a confidence in-
terval of 95%.
RESULTS
The mean age of participants was 60.54±7.07 
(46–75) years, and the mean time from the onset of 
menopause was 11.45±6.62 (1–24) years. After the re-
sults of DEXA, the patients were divided into three 
groups according to the lowest BMD at the lumbar 
spine, the mean value from total neck and/or femo-
ral neck: healthy controls with T-score ±1 SD; osteo-
penia with T-score from -1.1 to -2.5 SD; osteoporosis 
with T-score ≤-2.5 SD (Fig. 1).
There was a significant difference in age 
(healthy controls 56.6±6.58 y, osteopenia 60.21±6.19 
y, osteoporosis 62.93±7.59 y; p=0.015) and the du-
ration of menopause (healthy controls 7.56±4.79 y, 
osteopenia 9.92±5.72 y, osteoporosis 15.03±6.99 y, 
p<0.001) between the three groups, but no signifi-
cant difference was found in terms of smoking and 
alcohol consumption. The results of the subsequent 
analysis showed a strong proportional relation-
ship (r=0.836; p<0.001) between age and duration of 
menopause in the studied groups. As a threshold val-
ue of the age above which the risk of osteoporosis in-
creases, we defined 62.5 years (AUC=0.647 (0.518–
0.775); p=0.027) with a sensitivity of 56.7% and a 
specificity of 70.4%. As a threshold value for the du-
ration of menopause, above which the risk of osteo-
porosis increases, we defined 12.5 years (AUC=0.738 
(0.616–0.860); p<0.001) with sensitivity of 63.3% and 
specificity of 72.2%. From the analysis we can say 
that 70% of the changes in bone density are due to 
the long duration of menopause and the advanced 
age of the patients. 
Nevertheless, a negative correlation was found 
in the whole group between diastolic BP and BMD at 
the level of lumbar spine and femoral neck (respec-
tively T-score L1-L4 r=-0.311, p=0.004; BMD L1-L4 
r=-0.284, p=0.009; T-score neck r=-0.219, p=0.045; 
BMD neck r=-0.232, p=0.034). This relationship was 
maintained after considering age (respectively T-
score L1-L4 r=-0.307, p=0.005; BMD L1-L4 r=-0.280, 
p=0.01; T-score neck r=-0.213, p=0.05; BMD neck r=-
0.226, p=0.04), body mass index (BMI) (respective-
ly T-score L1-L4 r=-0.303, p=0.005; BMD L1-L4 r=-
0.275; p=0.012; T-score neck r=-0.208, p=0.05; BMD 
neck r=-0.221, p=0.04) and waist circumference (re-
spectively T-score L1-L4 r=-0.302, p=0.005; BMD L1-
L4 r=-0.224, p=0.012; T-score neck r=-0.206, p=0.06; 
BMD neck r=-0.220, p=0.046). The negative correla-
Fig. 1. Distribution of the subjects according to T-score
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tion between diastolic BP and BMD remained signif-
icant, but only at the level of lumbar spine after con-
sidering the duration of menopause (T-score L1-L4 
r=-0.276, p=0.012; BMD L1-L4 r=-0.245, p=0.026) 
and body weight (respectively T-score L1-L4 r=-
0.280, p=0.01; BMD L1-L4 r=-0.250, p=0.023).
Subsequent analysis of BP values  and the pres-
ence of AH revealed that patients with AH predom-
inated. Women with known AH, who received an-
tihypertensive therapy, were 61% of the total cases. 
They were with optimal BP levels (mean systolic BP 
126±12 mmHg; mean diastolic BP 77±7 mmHg). 
Women with newly diagnosed and respectively un-
treated AH were 8% of the cases and were classified 
as stage I AH. Their mean systolic (136±8 mmHg) 
and diastolic BP (8±6 mmHg) were significantly 
higher compared to the patients with known AH (re-
spectively p=0.039 and p<0.001). In addition, a pos-
itive correlation was found between age (r=0.395; 
p<0.001) and duration of menopause (r=0.249; 
p=0.022) with the stages of AH. However, a signif-
icant increase was found in the age of women ac-
cording to the presence of AH and its stages (from 
57.76±6.57y in subjects without AH to 67.6±4.25 y in 
the group of stage III AH, p=0.001 ), but the trend to 
increase the duration of menopause according to the 
presence of AH and its stages did not reach statistical 
significance (p=0.06).
Although AH predominated in the studied 
population, in subjects with changes in bone densi-
ty (osteopenia and osteoporosis) a significantly high-
er proportion of women with AH was observed (Fig. 
2). When performing additional analyses, it was 
found that the presence of AH was an independent 
risk factor for bone health in postmenopausal wom-
en (OR=2.14 (0.686–6.703); p=0.015). Because there 
was a significant difference in age between patients 
with and without AH (61.76±6.99 y vs. 57.76±6.57 y; 
p=0.015, respectively), and in the groups—according 
to BMD, we suggested that the established negative 
impact of AH on bone health could be age-modulat-
ed. This was confirmed by the calculated higher cu-
mulative risk to bone health after considering the age 
(OR=5.66 (0.839–6.462); p=0.017).
Тhe analysis of the mean values  of T-score and 
BMD according to the stage of AH revealed sever-
al differences, although not significant. In women 
with stage III AH the lowest bone indices were ob-
served at the level of L1-L4 (T-score -1.46±1.50 SD; 
BMD 1.00 ± 0.18 g/cm2 for L1-L4), femoral neck (T-
score -1.77±1.11 SD; BMD 0.78±0.15 g/cm2) and total 
neck (T-score -1.20±1.16 SD; BMD 0.85±0.15 g/cm2). 
These results could be associated with a negative im-
pact on the bone of the target organ damage, as well 
as the older age of patients in this group. The estab-
lished better parameters in stage II AH in the femo-
ral region (femoral neck T-score -1.42±0.83 SD, BMD 
0.85±0.12 g/cm2; total neck T-score -0.61±1.00 SD, 
BMD 0.93±0.13 g/cm2) compared to subjects with-
out AH (femoral neck T-score -1.60±0.68 SD, BMD 
0.82±0.09 g/cm2; total neck T-score -0.95±0.81 SD, 
BMD 0.89±0.10 g/cm2) and compared to subjects 
with stage I AH (femoral neck T-score -1.55±0.78 SD, 
BMD 0.82±0.11 g/cm2; total neck T-score -0.77±1.03 
SD, BMD 0.91±0.13 g/cm2) suggested the presence of 
a protective effect in the group of stage II AH. There-
fore, we hypothesized that the use of antihyperten-
sive drugs could explain the observed differences, as 
women without AH and individuals with newly di-
agnosed AH, who are in the group of stage I AH, did 
not receive antihypertensive therapy. 
The potential pleotropic effect of antihyper-
tensive drugs on bone was supported by the estab-
lished mean values of T-score and BMD after sep-
aration of women with newly diagnosed (respec-
tively untreated) AH. After recalculations in sub-
jects with treated stage I AH the best values  of BMD 
were reported (L1-L4 T-score -0.90±1.05 SD; BMD 
1.07±0.12 g/cm2; femoral neck T-score -1.35±0.73SD; 
BMD 0.85±0.10 g/cm2; total neck T-score -0.55±1.12 
SD; BMD 0.94±0.14 g/cm2). On the other hand, in 
persons with newly diagnosed AH the lowest BMD 
was observed (L1-L4 T-score -1.85±1.04 SD, BMD 
0.94±0.13 g/cm2; femoral neck T-score -1.96±0.62 SD, 
BMD 0.76±0.09 g/cm2; total neck T-score -1.05±0.78 
Fig. 2. Distribution of arterial hypertension by groups
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SD, BMD 1.01±0.10 g/cm2). These results are com-
parable with the established parameters in stage III 
AH. Additionally, we found a significant difference 
in the duration of menopause between women with 
newly diagnosed AH and subjects with treated stage 
I A (14.14±6.09 y vs. 8.18±5.56 y, p=0.048) in the ab-
sence of a significant difference in age (60.43±6.65 
y vs. 58.27±5.33 y, p>0.05). On the other hand, sig-
nificant difference in age was observed between the 
subjects with newly diagnosed AH and women with 
stage III AH (60.43±6.65 y vs. 67.6±4.25 y, p=0.016) 
in the absence of significant difference in the du-
ration of menopause (14.14±6.09 y vs. 14.9±5.36 y, 
p>0.05). These results suggest that untreated AH is 
associated with worsening BMD parameters, espe-
cially in older women and in those with longer dura-
tion of menopause. 
Fig 3. Distribution according to the intake of 
antihypertensive drugs
Healthy Controls Osteopenia Osteoporosis
L1-L4 Neck Total L1-L4 Neck Total L1-L4 Neck Total
T-score (± SD)
АСЕi or АRB
Without 0.21 -0.64 0.04 -1.08 -1.67 -0.89 -2.30 -2.01 -1.25
With 0.15 -0.38 0.45 -0.72 -1.41 -0.64 -2.42 -2.08 -1.49
P < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Thiazides
Without 0.19 -0.54 0.21 -1.02 -1.63 -0.89 -2.18 -1.93 -1.26
With 0.16 -0.44 0.36 -0.73 -1.42 -0.55 -2.72 -2.28 -1.60
P > 0.05 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
BBs
Without 0.02 -0.44 0.31 -1.13 -1.70 -0.96 -2.40 -2.10 -1.47
With 0.42 -0.60 0.18 -0.65 -1.36 -0.54 -2.29 -1.94 -1.19
P < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Са-antagonists
Without 0.16 -0.58 0.18 -0.97 -1.59 -0.82 -2.35 -2.08 -1.42
With 0.18 -0.51 1.40 -0.60 -1.30 -0.47 -2.47 -1.70 -1.37
P > 0.05 < 0.05 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
BMD (g/cm2)
АСЕi or АRB
Without 1.21 0.95 1.01 1.05 0.81 0.89 0.88 0.76 0.85
With 1.19 0.98 1.06 1.09 0.84 0.93 0.89 0.77 0.82
P > 0.05 > 0.05 < 0.05 < 0.05 > 0.05 < 0.05 > 0.05 > 0.05 > 0.05
Thiazides
Without 1.20 0.96 1.03 1.06 0.81 0.89 0.90 0.77 0.85
With 1.19 0.97 1.05 1.09 0.83 0.93 0.85 0.76 0.81
P > 0.05 > 0.05 > 0.05 < 0.05 > 0.05 < 0.05 < 0.05 > 0.05 < 0.05
BBs
Without 1.18 0.97 1.05 1.04 0.80 0.88 0.87 0.75 0.82
With 1.23 0.95 1.03 1.10 0.84 0.94 0.91 0.80 0.86
P < 0.05 > 0.05 > 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
Са-antagonists
Without 1.19 0.96 1.04 1.06 0.82 0.90 0.88 0.76 0.83
With 1.24 1.11 1.19 1.11 0.85 0.95 0.88 0.81 0.89
P < 0.05 < 0.05 < 0.05 < 0.05 > 0.05 < 0.05 > 0.05 < 0.05 < 0.05
Table 1. Mean value of T-score and BMD according to the intake of some antihypertensive drugs in the studied groups
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Mean T-score and BMD were further adjust-
ed for antihypertensive therapy (Fig. 3 and Table 1), 
which included drugs from the groups of thiazide 
diuretics, ACEi, ARB, BBs and/or Ca-antagonists. 
Only two patients with osteopenia were receiving a 
loop diuretic. 
Analysis of the data showed better BMD pa-
rameters at the level of femoral neck and total neck 
in healthy controls taking ACEi or ARB. In the group 
of patients with osteopenia, the intake of these drugs 
was associated with a higher BMD, both in the femo-
ral region and at the level of the lumbar spine. How-
ever, no positive effect was found in the group of pa-
tients with osteoporosis. Similar results were ob-
served according to thiazides. On the other hand, 
BBs intake was positively associated only with lum-
bar BMD in healthy controls. In patients with osteo-
penia and osteoporosis, better BMD parameters were 
observed, both in the femoral region and at the level 
of lumbar spine. Ca-antagonist intake was positively 
associated with BMD, both in the femoral region and 
at the level of lumbar spine in healthy controls and in 
patients with osteopenia. In patients with osteoporo-
sis, there was a positive association with BMD only at 
the level of femoral neck and total neck. 
Initial analysis showed no difference between 
the levels of bone metabolic markers and the values 
of BP, the presence of AH or its stage. This was found 
after considering the use of antihypertensive drugs in 
women with osteoporosis (Fig. 4). The results showed 
that women with osteoporosis taking the discussed 
antihypertensive drugs had significantly lower levels 
of osteocalcin (p<0.05). The same trends were main-
tained for Beta crossLaps and intake of ACEi or ARB, 
BBs and/or Ca-antagonists, as well as for the ratio of 
Pyrilinks D/creatinine in urine and intake of ACEi 
or ARB, thiazide diuretic and/or BBs. However, there 
was no significant difference (p>0.05) in the levels of 
Beta crossLaps according to the intake of thiazide di-
uretic and in the ratio of Pyrilinks D/creatinine in 
the urine according to the intake of a Ca-antagonist.
In the analysis of fracture risks, a positive cor-
relation was found between diastolic BP and both the 
10-year risk of MOF (r=0.252; p=0.021) and the 10-
year risk of HF (r=0.282; p=0.009). This relationship 
was maintained for the two fracture risks after con-
sidering age (respectively r=0.272; p=0.013 for MOF, 
and r=0.285; p=0.009 for HF), body weight (re-
spectively r=0.224; p=0.042 for MOF, and r=0.251; 
p=0.022 for HF), BMI (respectively r=0.249; p=0.023 
for MOF and r=0.275; p=0.012 for HF) and waist cir-
cumference (respectively r=0.245; p=0.025 for MOF 
and r=0.274; p=0.012 for HF). After considering the 
duration of menopause, only the correlation between 
diastolic BP and HF remained positive (r=0.235; 
p=0.033).
In addition, a significant difference in frac-
ture risk was found according to the presence of 
AH and its stage, both in terms of the 10-year risk 
of MOF and the 10-year risk of HF (Table 2). Recal-
culation of fracture risks after separation of women 
with newly diagnosed (respectively untreated) AH 
Fig. 4. Comparative analysis of the levels of osteocalcin 
(ng/mL), Beta crossLaps (ng/mL) and Pyrilinks D/
creatinine in urine (nmol/mmol) according to medication 
intake in women with osteoporosis




10-year risk of a major osteoporotic 
fracture (MOF) (%) 8.45±3.65 9.58±4.20 9.34±4.39 13.70±7.30 3.39 0.026
10-year risk of hip fracture (HF) (%) 1.23±0.92 1.66±2.34 1.58±1.50 3.29±3.44 3.22 0.039
Table 2. Mean values  of the 10-year risk of MOF and HF according to AH stages (mean ± SD)
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revealed the lowest 10-year risk of MOF and HF in 
subjects with stage I AH and in those without AH 
(respectively MOF 7.78±3.28%, HF 0.70±0.78% and 
MOF 8.45±3.65%, HF 1.23±0.92%, p>0.05), while in 
women with newly diagnosed AH the fracture risks 
were comparable to those in stage III AH (respec-
tively MOF 12.4±4.12%, HF 3.16±3.21% and MOF 
13.70±7.30%, HF 3.29±3.44%, p>0.05). No additional 
relationship between the intake of antihypertensive 
drugs and fracture risks was established.
DISCUSSION 
It is well known that older age and longer dura-
tion of menopause are the leading unmodifiable risk 
factors for the development of osteoporosis in post-
menopausal women. According to the present study, 
changes in bone density were determined in about 
70% of these two risk factors. However, our results 
identified AH as an additional determinant of post-
menopausal bone health. Our data are comparable to 
the results of a number of other clinical studies and 
meta-analyses (1,3,4,11), but do not overlap with the 
conclusion of Hanley et al. that AH is associated with 
an increase in bone mass (5), as well as with the con-
clusion of Hijazi et al., who did not establish a link 
between osteoporosis and AH in adult postmeno-
pausal women (7).
The negative correlation found between diastol-
ic BP and BMD, with established positive correlation 
between diastolic BP and fracture risks, corresponds 
to the results of Jeon et al. (12), while other authors 
also report a negative impact of systolic BP on bone 
health (2). In addition, we found that not only high-
er diastolic BP but also the presence of AH as well 
as its stage could be relevant to postmenopausal os-
teoporosis, as subjects with treated stage I AH  pre-
sented the best BMD values  at the level of lumbar 
spine, femoral neck and total neck, as well as the low-
est fracture risks. On the other hand, in women with 
newly diagnosed (respectively untreated) AH and in 
the group of stage III AH, the lowest BMD and the 
highest fracture risk were reported. These results 
suggest that untreated AH is associated with wors-
ening BMD parameters, especially in older women 
and in those with longer duration of menopause. In 
addition, our data support assertions about the po-
tential pleotropic effects of antihypertensive drugs 
on bone (7,8). The established better BMD values  in 
the different skeletal regions in the group of healthy 
controls and among women with osteopenia taking 
ACEi/ARB, thiazide diuretic, BBs and/or Ca-antag-
onists raise the question of the importance of these 
antihypertensive drugs in prevention and prophylax-
is of osteoporosis. On the other hand, the lack of such 
observations in the group of women with osteoporo-
sis taking ACEi/ARB and/or thiazide diuretics sug-
gests a loss of protective effect in case of osteoporosis 
or a negative impact of additional factors such as old-
er age, longer duration of menopause or concomitant 
comorbidities. In addition, we found that the intake 
of the discussed antihypertensive drugs in the group 
of osteoporosis was associated with a lower level of 
bone metabolism.
Based on the obtained results, we assume that 
the timely inclusion of antihypertensive drugs is es-
sential, as their presumed pleotropic effects on bone 
probably depend on the duration of their intake and 
on the initial bone parameters at which antihyper-
tensive treatment was started. We also believe that 
properly selected and timely initiated antihyperten-
sive therapy could be useful in preventing potential 
fractures.
LIMITATIONS 
Several limitations should be considered in the 
interpretation of our data. The small sample size 
might attenuate the strength of the established asso-
ciations between bone health, AH and the considered 
antihypertensive drugs. In addition, the duration of 
AH and the duration of antihypertensive treatment 
have not been analyzed. On the other hand, we did 
not evaluate bone microarchitecture, which is an ad-
ditional determinant of bone strength. Due to the 
cross-sectional nature of the study, the causal rela-
tionship between bone health and BP, AH or antihy-
pertensive treatment cannot be determined. 
CONCLUSION
According to the obtained results, we assumed 
that AH is risk factor for bone health in postmeno-
pausal women, as it is associated with lower BMD and 
higher fracture risk. In addition, we found differenc-
es according to the stage of AH and antihyperten-
sive therapy, which might be considered in the pre-
vention, prophylaxis and treatment of osteoporosis.
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